prostate and tumor News

The study revealed that when the loss of heterozygosity (LOH) was identical (concordant) in the tumors they were metastatic. New multifocal primary cancers had discordant LOH, meaning their LOH was not identical.

Several milestones achieved following its first year treating patients in Suffolk County, New York.

Visualase Inc. Selected to Present at Epilepsy Conference Highlighting New and Promising Epilepsy Therapies. Epilepsy Pipeline Update 2010 to Take Place February 25-26 in San Francisco.

Visualase Inc. was selected for a $2.1 million grant from the Cancer Prevention and Research Institute of Texas. The precision and control of the Visualase technology has made possible the ablation of tissue in areas such as brain and prostate.